BCAT-IN-4 - An Overview
The principal end position was the protection and tolerability of sifalimumab. Treatment-emergent adverse functions (AEs) and major AEs (SAEs) as well as their severity, consequence, and any connection to your study medication were being recorded from the investigator through the research. AEs were being regarded as more likely to be connected to e